A New Marker for Testicular Cancer
Author Information
Author(s): S. Metcalfe, K. Sikora
Primary Institution: Department of Surgery, Addenbrooke's Hospital, Ludwig Institute for Cancer Research
Hypothesis
Can the B5 test serve as a reliable marker for monitoring testicular cancer patients who do not show elevated levels of traditional markers?
Conclusion
The B5 test is a valuable addition to monitoring testicular cancer, especially for patients with normal aFP and βHCG levels.
Supporting Evidence
- B5 positivity was found in 80% of cancer patients compared to 20% in controls.
- Patients reverted to B5 negative status after successful tumor removal.
- B5 was sensitive in detecting tumor presence in patients with normal aFP and βHCG levels.
Takeaway
Doctors can use a new test called B5 to check for testicular cancer, even if other tests say everything is fine.
Methodology
The study involved testing 79 patients with testicular tumors using the B5 haemagglutination test and comparing it with standard markers.
Limitations
Some patients remained B5 positive without active disease, which could lead to false positives.
Participant Demographics
Patients attending a testicular tumor clinic over a period of 16 months.
Want to read the original?
Access the complete publication on the publisher's website